This phase I/II trial is evaluating a combination of two intravenous drugs (Isatuximab and Cemiplimab) for patients with multiple myeloma that has gotten worse or not responded to prior treatment .
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to assess the safety and tolerability of a combination of two drugs (Isatuximab and Cemiplimab), and compare the overall response of this combination with isatuximab alone, in patients with relapsed/refractory multiple myeloma.
Recruiting Hospitals Read More